

# 2024 HIV and Hepatitis Prevention Program Snapshot

## Integrated Testing Services: HCV Screening


The Integrated Testing Services (ITS) program administered 1,010 hepatitis C (HCV) tests across 12 participating agencies in 2024.

This represents a 4% increase from 2023 and is 2% above the five-year average of 989 tests per year.

The HCV positivity rate (calculated by those individuals as having an active viral load) for 2024 was 4.65%, slightly higher than the five-year positivity rate of 3.46%.


The majority of individuals diagnosed with chronic HCV in ITS settings in 2024 (91%) reported a history of injection drug use, consistent with programmatic guidance for prioritized screening.

### ITS HCV Testing and Positivity 2020-2024



*Data are not de-duplicated. Numbers represent test encounters not unique individuals.*

### ITS HCV Diagnoses vs State Totals 2020-2024



The proportion of individuals diagnosed with chronic HCV in Iowa identified through ITS program activities increased to 9% of new diagnoses in 2024 as compared to 3% in 2023 and 5% over the five-year period represented.

Overall, Iowa has seen a total decline in newly reported chronic HCV cases of 39% between 2020 and 2024.

Preliminary analysis shows that 43% of all newly reported cases of HCV in Iowa were among people who inject drugs or who have a history of injection drug use (PWID) in 2024.